Jonathan M Peacock
CIK 1500241 · President and CEO · last filed 2025-05-12
Jonathan M Peacock is a President and CEO who has filed 39 SEC Form 4 insider transactions across 4 companies since 2010. The most recent filing, for AVTR, was dated May 12, 2025. Across all open-market trades the lifetime net is +$1.0M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $47.9M across reported positions. 9 SEC filings were submitted jointly with AMGEN INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
BLPH price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
THOUSAND OAKS, CA 91320-1799
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AVTR | Director | 219,815 | $16.16 | $3.55M | $103.6K | 9 | 2025-05-12 |
| Bellerophon Therapeutics, Inc. (BLPH) Delisted | Director | 157,033 | $0.01 | $1.9K | $900.1K | 18 | 2021-04-02 |
| Kite Pharma, Inc. (KITE) Delisted | Director | 70,374 | — | — | $0 | 3 | 2017-06-22 |
| AMGN | EVP & CFO | 94,414 | $469.56 | $44.33M | $0 | 8 | 2013-10-29 |
Recent Filings
39 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-05-12 | AVTR | Grant (A) | +17,100 | $0 | EDGAR |
| 2025-04-29 | AVTR | Buy (P) | +8,091 | $103.6K | EDGAR |
| 2024-05-13 | AVTR | Grant (A) | +8,477 | $0 | EDGAR |
| 2023-05-15 | AVTR | Grant (A) | +9,808 | $0 | EDGAR |
| 2022-05-16 | AVTR | Grant (A) | +6,693 | $0 | EDGAR |
| 2022-04-05 | AVTR | Grant (A) | +1,215 | $0 | EDGAR |
| 2021-04-02 | Bellerophon Therapeutics, Inc. (BLPH) Delisted | Grant (A) | +15,308 | $0 | EDGAR |
| 2021-03-01 | AVTR | Grant (A) | +7,236 | $0 | EDGAR |
| 2020-02-25 | AVTR | Grant (A) | +11,319 | $0 | EDGAR |
| 2020-01-27 | Bellerophon Therapeutics, Inc. (BLPH) Delisted | Grant (A) | +350,000 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.